medicina

IMPACT FACTOR 2.4

Indexed in: PubMed

CITESCORE 3.3

an Open Access Journal by MDPI

Clinical Advances in Interstitial Lung Diseases

Guest Editors:

Dr. Yoshiaki Zaizen
Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

Dr. Masaki Okamoto
Division of Respirology, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan

Deadline for manuscript submissions:
closed (20 May 2024)

Message from the Guest Editors

The field of interstitial lung disease has experienced significant progress over the past decade. The cryobiopsy method has been established as a method for obtaining tissue samples for the pathology. With the improvement of analysis technology using artificial intelligence, there have also been remarkable developments in genome classification. In pharmacological therapy, two antifibrotic agents, pirfenidone and nintedanib, have provided alternatives to conventional corticosteroid-based anti-inflammatory therapy and are effective in the treatment of idiopathic and progressive pulmonary fibrosis. Additionally, today, many compounds with antifibrotic activity are in development. Scientific evidence is also slowly but surely establishing non-pharmacological therapies, such as respiratory rehabilitation. We now need to understand the pathophysiology and prognoses of patients with interstitial lung disease and provide appropriate treatment and management.

In this Special Issue, we welcome authors to submit papers that will provide more reliable evidence of the advances in the diagnosis and treatment of interstitial lung disease.

medicina

IMPACT FACTOR 2.4 | Indexed in: PubMed | CITESCORE 3.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius
Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Medicina Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/medicina
medicina@mdpi.com